WO1994007480A1 - Polyamine derivatives as anti-cytomegaloviral agents - Google Patents
Polyamine derivatives as anti-cytomegaloviral agents Download PDFInfo
- Publication number
- WO1994007480A1 WO1994007480A1 PCT/US1993/008517 US9308517W WO9407480A1 WO 1994007480 A1 WO1994007480 A1 WO 1994007480A1 US 9308517 W US9308517 W US 9308517W WO 9407480 A1 WO9407480 A1 WO 9407480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bis
- compound
- compounds
- mixture
- formula
- Prior art date
Links
- 0 CC1*=C2*1C1(C3)C2CCC3C1 Chemical compound CC1*=C2*1C1(C3)C2CCC3C1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
Definitions
- CMV Human cytomegalovirus
- CMV is ubiquitously transmitted in all populations. However, risk to CMV infections varies considerably in different geographic areas. Infected individuals may transmit the virus in urine, saliva, cervical secretions, semen, feces, milk, or infected blood and organs. Molecular analysis of the DNA of CMV isolates reveals minor strain-specific differences that are useful markers in epidemiological investigation. CMV is highly host-specific and cannot be propagated in laboratory animals or in most non-human cell cultures. Therefore, experiments designed to be predictive of CMV activity generally are restricted to human cell lines that have resident the CMV virus or have become infected with CMV. It is well known that aliphatic polyamines, such as spermine and spermidine, play a role in cell growth and proliferation.
- Putrescine is formed by a decarboxylation of ornithine by ornithine decarboxylase (ODC) and this is a highly regulated stage in the biosynthesis of spermidine and spermine.
- ODC ornithine decarboxylase
- the human cytomegaloviruses are a subgroup of agents within the herpes group of viruses, all of which have the propensity for remaining latent in man. No specific therapy is generally available for CMV infections.
- CMV agents afford less cell and/or tissue toxicity compared to other agents in use.
- herpes simplex type 1 and type 11 and varicella-zoster virus is compared to other herpes viruses, herpes simplex type 1 and type 11 and varicella-zoster virus.
- derivatives are effective therapeutic agents when used against cell cultures infected with CMV.
- An object of the present invention is the use of the describe polyamine derivatives as therapeutic agents against CMV.
- This invention relates to methods of use of certain polyamine derivatives in the treatment of patients suffering from CMV disease states and to pharmaceutical compositions containing these polyamine derivatives.
- this invention relates to a method for the treatment of patients suffering from CMV infections which comprises administering a therapeutically effective amount of a compound of the formula (I): wherein Z is a
- each R group independently is hydrogen, a C 1 -C 6 saturated or unsaturated hydrocarbyl, or -(CH 2 ) x -(Ar)-X wherein Ar is phenyl or napthyl, X is H, C 1 -C 6 alkoxy, halogen C 1 -C 4 alkyl, wherein x is an integer 0, 1, or 2; with the proviso that both R groups cannot be hydrogen; or said compounds of formula I can be a pharmaceutically acceptable acid
- compounds of formulae (I) provide an anti-CMV effect in patients in need thereof.
- Compounds of formuale I generally produce effective treatment without similar delayed toxicity effects produced by other agents.
- the present invention relates to the use of novel compounds of the formula (I) for CMV infections, or more specifically to the novel compounds of formula (la) and (lb).
- novel compounds of formula (Ia) are of the formula:
- Z 1 is a branched chain (C 2 -C 6 ) alkyl moiety; m is 7 or 8; and each R group independently is hydrogen, a C 1 -C 6 saturated or unsaturated hydrocarbyl, or -(CH 2 ) x -(Ar)-X wherein Ar is phenyl or napthyl, X is H, C 1 -C 6 alkoxy, halogen C 1 -C 4 alkyl, wherein x is an integer 0, 1, or 2; with the proviso that both R groups cannot be hydrogen; or said compounds of formula la can be a pharmaceutically acceptable acid addition salt thereof.
- novel compounds of formula (lb) are of the formula:
- Z 2 is a straight chain (C 2 -C 6 ) alkyl moiety; m is 7 or 8; each R group independently is hydrogen, a C 1 -C 6 saturated or unsaturated hydrocarbyl, or -(CH 2 ) x -(Ar)-X wherein Ar is phenyl or napthyl, X is H, C 1 -C 6 alkoxy, halogen C 1 -C 4 alkyl, wherein x is an integer 0, 1, or 2; with the proviso that both R groups cannot be hydrogen; or said compounds of formula lb can be a pharmaceutically acceptable acid addition salt thereof.
- the center alkylene moiety of compounds of the formula (I) is a saturated, straight-chain hydrocarbyl radical comprising 7 or 8 carbon atoms, i.e., "(CH 2 ) 7 " or "(CH 2 ) 8 ".
- Z is understood to mean a saturated hydrocarbylene radical of straight (Z 2 ) or branched-chain configuration (Z 1 ) comprising 2 to 6 carbon atoms including, but not limited to, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 ) 2 CH 2 -, -CH 2 (CH 2 ) 3 CH 2 -, -CH 2 ( CH 2 ) 4 CH 2 -,
- R is an unsaturated hydrocarbyl moiety
- acceptable acid addition salt encompasses both organic and inorganic acid addition salts including, for example, those prepared from acids such as hydrochloric, hydrofluoric, sulfuric, sulfonic, tartaric, fumaric, hydrobromic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric, benzoic, ascorbic, p-toluenesulfonic,
- R is as defined in formula (I) except when R is X-(Ar)-(CH) x , x cannot be zero.
- a Boc is the t-butoxycarbonyl protecting group, and Y is tert-butyl.
- the initial step of this process entails an N-alkylation of the appropriate diamine with 2 equivalents of acrylonitrile by heating reactants, either in a suitable solvent or neat, according to standard conditions well known in the art.
- the resulting cyano derivatives (2) are chemically reduced by reaction with hydrogen in the
- hydrohalic salts according to standard procedures well known in the art.
- a catalyst PtO 2
- acetic acid containing 8 equivalents of hydrochloric or hydrobromic acid a suitable solvent
- other reducing systems e.g., reduction with lithium aluminum hydride, may also be utilized to produce compounds of formula (3).
- the hydrohalic salts are neutralized with base and the nitrogen atoms are protected, preferably with di-t-butyldicarbonate according to standard operating conditions well known in the art.
- the tetra N-protected amines (4) are alkyiated by reacting (4) with the
- monosubstitution of compounds of formula (4) is effected by reacting about 1 to about 1.5 equivalents of the alkyl halide with subsequent isolation of the monosubstituted compound according to standard procedures well known in the art and optionally further reacting the monosubstituted compound with the desired different alkyl halide.
- N-protective groups of compound (5) are removed by standard procedures, e.g., treatment with acid, preferably HCl, in the presence of a suitable solvent or solvent system, e.g., diethyloxide in ethanol, to obtain the desired products (6).
- acid preferably HCl
- solvent or solvent system e.g., diethyloxide in ethanol
- compounds of formula (3) and their otherwise prepared homologs may be subjected to a reductive alkylation using an appropriate aldehyde.
- the reduction is effected by hydrogenation in the presence of PtO 2 or sodium cyanoborohydride according to well known procedures. This procedure does not generally require protection of the nitrogen atoms of the intermediates.
- n is an integer 2 to 6 describing a straight chain alkylene moiety
- Boc is the t-butoxycarbonyl protecting group
- R is as defined in formula (I)
- Ms is mesyl and R 1 is hydrogen, methyl or ethyl.
- This synthesis is initiated by reductive alkylation techniques well known in the art using an amino alcohol (7) and an appropriate aldehyde to form R- substituted amino alcohols (8).
- the nitrogen atom is protected, preferably with di-t-butyldicarbonate, according to standard operating conditions well known in the art, to yield the N-protected amino alcohols (9) which are converted to their mesylates (10) by known reaction conditions, e.g., reaction with mesylchloride in the presence of pyridine, preferably in a solvent such as CH 2 CI 2 .
- the mesylate is subjected to alkylation with an N-protected diamine (i.e., BocNH(CH 2 ) m NHBoc) in the presence of potassium t-butoxide in a solvent such as DMF.
- N-protected diamine i.e., BocNH(CH 2 ) m NHBoc
- the so-produced tetra N-protected tetramines (11) are deprotected as in Scheme A.
- alkylation, N-protection, mesylation, alkylation and deprotection procedures all employ techniques and reaction conditions which are well known in the art.
- N-alkylation entails the reaction of an appropriate dihaloalkane (13) with excess quantities (10x) of ethylene diamine (12) by heating the reactants at reflux temperatures in a suitable solvent, e.g., ethanol.
- intermediates (14) may be effected by N-protection, alkylation with the appropriate alkyl halide, and
- the alkylation can be carried out by the reductive alkylation procedures without N-protection as alternatively described for Reaction
- R and Z 1 are as generically defined for formula (la), and R 1 is hydrogen.
- the appropriate primary amino alcohol (15) containing a branched chain hydrocarbyl moiety (i.e., Z 1 ) is prepared by standard procedures well known in the art. If desired, the primary amine can at this point be converted to a secondary amine (16), by a reductive alkylation with the appropriate aldehyde.
- the amino alcohol is reacted as described in Reaction Scheme A by standard conditions well known in the art to effect protection of the amines with an appropriate N-protecting group such as Boc (17).
- the mesylates of the N-protected amino alcohols (18) are prepared and are
- BocNH(CH 2 ) m NHBoc is effected by reacting the diamine with about 1.0 to 1.5 equivalents of one of the mesylates (18) with subsequent isolation of the monosubstituted compound and optionally further reacting the
- Scheme E can be used to obtain intermediates of the formula (25) which can be subjected to alkylation of the N-terminal groups in a manner analogous to that described in Reaction Scheme A prior to de-protection,
- the initial step of the process entails a reductive alkylation wherein the appropriate diamine is reacted with hydrogen gas and 2 equivalents of benzaldehyde in the presence of a catalyst such as PtO 2 to yield the N-protected diamine (21) under standard conditions well known in the art.
- the N-protected diamine (21) is then alkyiated with 2 equivalents of the appropriate vinyl ketone (22) in a suitable solvent such as methanol using standard
- oximes (24) are reduced to the corresponding N-protected di-primary amines (25) by reaction with lithium aluminum hydride (LAH) in the presence of AlCI 3 in a
- N-protected di-primary amines (25) can be further alkyiated with an appropriate aldehyde prior to deprotection in a manner analogous to that described for Reaction Scheme A.
- a preferred method for preparing compounds of formula [I] wherein -(CH)x-(Ar)-X represents phenethyl or naphthylethyl, particularly wherein Z is 3 and m is 8, is the reaction of an aroylchloride according to the method depicted in Reaction Scheme F wherein depicted in Scheme F Bn is benzyl, ⁇ is phenyl, and LAH is lithium aluminum hydride.
- the foregoing reaction is a preferred method for the preparation of one particular compound which entails N-alkylation of a partially protected intermediate [27] with an arylacetyl chloride [28] in the presence of triethylamine, using an inert solvent, to form an amide [29] which is chemically reduced, preferably with LAH, and the resulting product [30] is catalytically de-benzylated (H 2 Pd/C) to form the desired end product [31].
- These steps entail reaction techniques and procedures well known in the art.
- the same reaction scheme can be applied for the preparation of other compounds of formula [I]; adoption of the technique being with the usual caveats well
- reaction scheme depicts the preparation of compounds wherein Ar is phenyl, the first step of which is a LAH reduction effected according to procedures published is the art (Bui. Soc. Chim. Fr., Part 2, 165-7 (1979)).
- this reaction scheme can be expanded to include napthyl and X-substituted intermediates which will not be adversely affected by the reaction conditions.
- the N-protection uses the t-butoxycarbonyl protecting groups which are put on and taken off according to standard techniques already mentioned hereinabove.
- the N-protected compounds are alkyiated by reaction with an appropriate dihaloalkane using standard and well known procedures.
- mesylates [40] are alkyiated with two equivalents of an N-protected amine bearing an appropriate unsaturated
- hydrocarbyl moiety e.g., N-(t-butoxycarbonyl)-2,3-butadienylamine.
- a so-obtained tetra protected tetramine [41] is then readily de-protected to produce the desired compounds [ 42 ].
- the alkyl thioether is treated with a peracid according to known conditions. Suitable oxidizing agents are H 2 O 2 and NaIO 4 , but meta-chloroperoxybenzoic acid is preferred. In effecting the oxidation to a sulfinyl derivative 1 molar equivalent (per alkylthioether moiety) is used and 2 molar equivalents of the peracid will yield the sulfonyl
- the oxidations are effected at temperatures of about 0oC to room temperature in solvents which
- Preferred solvents are CH 2 Cl 2 , CHCl 3 , aeetic acid, and ethyl acetate.
- reaction scheme I depicts a method of preparation of the compounds of formula I.
- Ts is a tolunesulfonyl substituent
- DEAD is diethyl azodicarboxylate
- THF is tetrahydrofuran
- TFA is trifluoroacetic acid
- Boc is the t-butoxycarbonyl protecting group.
- the reaction scheme is illustrative, and not limiting, of the chemistry depicted, wherein it is understood the reaction scheme can be expanded to include variations of m, Z, and R as defined in formula I.
- the reaction scheme can be expanded to include the variations of Ts protecting group by various other arylsulfonyl groups beside toluenesulfonyl, such as mesitylenesulfonyl,
- Initial step (a), of scheme I is the formation of compound [44] by reaction of N-t-butyloxycarbonyl-p-tolunesulfonamide with a chloroalkyl alcohol in the
- step (g) when Z 4.
- Step (b) involves the reaction of two equivalents of Compound [44] with a suitably protected diaminoalkane, e.g., as shown a di-tolsyl protected alkylydiamine
- TsNH(CH 2 )mNHTs can be used to form intermediate [45].
- intermediate [45] can be accomplished by reaction [43] with the approximately 1 equivalent of the alkyldiol shown in the presence of TPP and DEAD in a suitable solvent, such as THF to form intermediate [49].
- Intermediate [49] can then be reacted with a protected diaminoalkane, e.g., as shown, the ditosyl protected alkyldiamine (TsNH(CH 2 )mNHTs), to form intermediate [45].
- This route of synthesis, step (g) is suitable in those instance when Z is not 4.
- deprotection with a stronger acid can be used to form structures of compound [48] where in the substituted R group is hydrogen.
- a stronger acid e.g. HBr
- the more general route of deprotection would be to directly treat [45] with a strong acid, e.g. HBr, to directly form [48] wherein R is
- intermediate [46] can be reacted with a R-alkyl halide in the presence of hydride ion and sodium iodide to give the compound of formula [47].
- Compounds of formula [47] can then be deprotected upon treatment with acid, to form the compounds of formula [48], wherein R is other than hydrogen.
- reaction scheme J depicts the preparation of N,N'-Bis[3-(ethylamino)propyl]1,7-heptanediamine tetrahydrochloride.
- certain parts of the reaction scheme can be expanded to include the variations of m and R of formula I, however, Z is generally limited to being propyl, wherein Z is 3.
- the R group introduced in scheme J is shown as ethyl, but the reaction scheme is not limited only to ethyl derivatives but may include those R groups of formula I to form corresponding R substituted derivatives.
- step (a) of scheme J is a protection of the nitrogens of formula [50] by reaction with aqueous HCHO using standard and well known procedures to give the corresponding diaza ring systems in compound [51].
- step (b) the N-protected amines [51] are alkyiated by reacting with the appropriate acid anhydride according to standard alkylation procedures known to those skilled in the art. When it is desired to provide compounds of the formula (I) wherein both R groups are the same, about 3-6 equivalents of the acid anhydride is reacted.
- monosubstitution of compounds of formula [52] is effected by reacting about 1 to about 1.5 equivalents of the acid anhydride with subsequent isolation of the monosubstituted compound according to standard procedures well known in the art and optionally further reacting the monosubstituted compound with the desired different acid anhydride or alkyl or aryl halide.
- the resulting acetylated derivatives of [52] are then chemically reduced (step c) by reaction with lithium aluminum hydride in anhydrous conditions according to standard procedures well known in the art.
- the term "patient” refers to a warm-blooded animal such as a mammal which is afflicted with a neoplastic disease state. It is understood that dogs, cats, rats, mice, horses, bovine cattle, sheep, and humans are examples of animals within the scope of the meaning of the term.
- cytomegaloviral infection refers to an abnormal state or condition characterized by an active or latent CMV infection or state whenever the patient has virus residing active or dormant in the
- disease state comprises administering to such patient an amount of a compound of the formula (I) which is
- controlling CMV infection refers to slowing, interrupting, arresting or stopping a CMV
- a compound of formula (I) in effecting treatment of a patient afflicted with a CMV infection or prophylatic treatment to prevent infection a compound of formula (I) can be administered parenterally in any manner which makes (I) bioavailable in effective amounts including for example, by intraperitoneal (i.p.), subcutaneous (s.c), or intravenous (i.v.) injection.
- Administration by intravenous injection is preferred.
- a therapeutically effective dose or amount can readily be determined by the attending diagnostician and is a function of a number of factors including, but not limited to, the species of mammal, its size, age and general health, the specific CMV infection involved, the stage of the CMV infection, the compound selected and mode of administration, the bioavailability characteristics of the preparation administered, the dose regimen selected, and use of concomitant medication.
- the correct amount for any specific situation can be readily determined by those skilled in the art using conventional range finding
- a therapeutically effective amount of (I) will vary from about 1 milligram per kilogram of body weight per day (mg/kg/day) to about 500 mg/kg/day and preferably will be about 5 mg/kg/day to about 50 mg/kg/day. It is believed that compounds of the formula (I)
- a patient may have so as to prolong the survivability of the patient beyond that expected in the absence of such
- compositions for parenteral administration for compounds of the formula (I) comprise a therapeutically effective amount of one or more compounds of the formula (I) in an admixture with one or more pharmaceutically acceptable excipients, Such compositions are prepared in conventional manner well known in the art of pharmaceutical science. The amounts of the active ingredient(s) in a unit dosage form and the dosage regimen are adjusted to provide a sustained duration of a sustained duration of a sustained duration of a sustained duration of administrados, a sustained duration, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
- compositions are substances that are chemically inert to the active compound(s) and have no detrimental side effects or toxicity to mammals under the conditions of use.
- Suitable excipients include solvents such as water, alcohol, and propylene glycol, surface active agents, suspending agents, lubricants, flavors, colorants, and the like.
- Such carriers and excipients are known to those in the art and are disclosed, for example, in texts such as Remington's Pharmaceutical Manufacturing, 13th Edition, Mack Publishing Co., Easton, PA (1965).
- Injectable dosage forms of a solution or suspension of (I) can be prepared, for example, in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid such as water and oils with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
- a pharmaceutical carrier which can be a sterile liquid such as water and oils with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
- oils which can be employed in these preparations are those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil and mineral oil.
- water, saline, aqueous dextrose and related sugar solution ethanols and glycols such as propylene glycol or
- polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
- certain subgeneric and certain specific compounds are more efficient in their end-use applications than other members of the generic class.
- those compounds wherein Z is -CH 2 CH 2 CH 2 - or -CH(CH 3 )CH 2 CH 2 - are most preferred.
- the symmetrical compounds are preferred.
- Compounds for which each R is independently methyl or ethyl are preferred for this method of use and compounds for which both R groups are methyl or both R groups are ethyl are preferred.
- N,N'-bis[3-(ethylamino)propyl]-1,7-diaminooctane and N,N'-bis[3-(ethylamino)propyl]-1,7-diaminoheptane are most preferred.
- the following examples are
- temperatures are in degrees Celsius and the following abbreviations are used: (g) is grams, (mol) is moles, (ml) is milliliters, (l) is liters, (lb/in 2 ) is pounds per square inch, (TLC) is thin layer chromatography, (THF) is
- tetrahydrofuran (DMF) is dimethylformamide
- mp melting point
- mm/Hg pressure expressed as millimeters of mercury
- bp boiling point.
- Step A N,N'-Bis(2-(cyano)ethyl)-1,8-octanediamine
- Step C 1,5,14,18-Tetra(t-butoxycarbonyl)-1,5,14,18-tetraazaoctadecane
- Step D 1,18-Bis(methyl)-1,5,14,18-tetra(t-butoxycarbonyl)-1,5,14,18-tetraazoctadecane
- Step E N,N'-Bis(3-(methylamino)propyl)-1,8-octanediamine tetrahydrochloride
- Step A 1,18-Bis(ethyl)-1,5,14,18-tetra(t-butoxycarbonyl)-1,5,14-18-tetraazaoctadecane
- Example 1 2.91 g (0.026 mol) of potassium t-butoxide, and 45 ml of DMF and cool to 0°C. Add 2.1 ml (0.026 mol) of iodoethane and stir at 0°C for 4 hours. Allow the mixture to warm slowly to room temperature and stir overnight.
- Step B N,N'-Bis(3-(ethylamino)propyl)-1,8-octanediamine tetrahydrochloride hemihydrate
- Step A 1-Ethyl-1,5,14,18-tetra-(t-butoxycarbonyl)- 1,5,14,18-tetraazaoctadecane
- Step B N-(3-Aminopropyl)-N'-(3-(ethylamino)propyl)-1,8-octanediamine tetrahydrochloride
- Step A N,N'-Bis[(phenyl)methyl]-1,7-heptanediamine
- Step C N,N'-Bis[(3-hydroxyimino)butyl]-N,N'-bis[(phenyl) methyl]-1,7-diaminoheptane
- step B Cool the reaction mixture obtained in step B to 0°C and to this mixture add a solution of hydroxylamine hydrochloride (4.38 g, 0.063 mol) and sodium bicarbonate (5.54 g, 0.066 mol) in water (40 ml). Stir the mixture at 0°C for 30 minutes and then stir at ambient temperature for 2 hours. Remove the solvent in vacuo and partition the residue between water (200 ml) and dichloromethane (200 ml). Wash the aqueous layer 3 times with 200 ml of dichloromethane each time. Combine the organic layers and dry over
- Step D N,N'-Bis[3-(amino)butyl]-N,N'-bis[(phenyl) methyl]-1,7-diaminoheptane
- Step E 2,16-Bis(methyl)-1,5,13,17-tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
- Step G N,N'-Bis[3-(methylamino)butyl]-1,7-diaminoheptane tetrahydrochloride
- Step A 1,17-Diethyl-2,16-dimethyl-1,5,13,17-tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
- Step B N,N'-Bis[3-(ethylamino)butyl]-1,7-diaminoheptane tetrahydrochloride
- Steps A and B 1,5,13,17-Tetraazaheptadecane
- Step C 1,5,13,17-Tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
- Step E N,N'-Bis[3-(ethylamino)propyl]-1,7-heptanediamine Treat 3,7,15,19-tetra(t-butoxycarbonyl)-3,7,15,19-tetraazaheneicosane (1.68 gm, 0.0024 mol) with HCl in methanol (50 ml, 1.0 N) and stir overnight. Filter the mixture and recrystallize the title compound from
- Step A N,N'-Bis-[2,2'-bis(cyano)ethyl]-1,8-diamino-octane Dissolve 28.8 gm (0.2 mol) of 1,8 diaminooctane in 250 ml of EtOH. Add 27 ml (0.41 mol) of acrylonitrile and gently reflux the mixture overnight. Remove the solvent at reduced pressure. Analysis shows desired material to be >95% pure.
- Step B 1,5,14,18-Tetraazaoctadecane tetrahydrochloride
- Step D 1,18,-Bis[(phenyl)methyl]-1,5,14,18-tetra(t-butoxycarbonyl)-1,5,14,18-tetraazaoctadecane
- Step E 1,18-Bis-[(phenyl)methyl]-1,5,14,18-tetraazaoctadecane•4HCl
- Step A N,N'-Bis(t-butoxycarbonyl)-1,8-octanediamine
- Step B 4-[[(Phenyl)methyl]amino]-butan-1-ol
- Step C 4-[N-(t-butoxycarbonyl)-N-[(phenyl)methyl]amino] butan-1-ol
- Step B Combine the butanol of Step B (17.7 g - 0.1 mol) and ditbutyldicarbonate in 100 ml of CH 2 CI 2 and stir the mixture overnight. Evaporate off the solvents, in vacuo, and flash chromatography of the residue, eluting from silica gel with 25% EtOAc/hexane to obtain the desired compound.
- Rf is .27 (silica gel plates eluted with 20% EtOAc/hexane).
- Step D 4-[N-(t-butoxycarbonyl)-N-[(phenyl)methyl]-amino]-lnethansulfonyl butane
- Step A Admix the products of Step A (5.16 gm - 0.015 mol) and of Step D of this example (10.7 g - 0.032 mol), Kt-BuO (3.92 gm), Nal 0.2 gm), and 60 ml DMF and stir the mixture for 72 hours at room temperature. Evaporate the solvent ( in vacuo) , take up the residue in 600 ml EtOAc and wash (2x) with 200 ml water. Dry the organic layer (MgSO 4 ), evaporate the solvents, and flash chromatograph the viscous residue on silica gel eluting with 20% EtOAc/hexane to obtain the desired product, Rf is 0.22 (silica gel plates eluted with 20% EtOAc/hexane).
- Step F 1,20-Bis[(phenyl)methyl]-1,6,15,20-tetraeicosane•4 HCl
- Step E Dissolve the product of Step E (4.7 gm) (0.0054 mol) in 5 ml EtOH and treat with 54 ml of 2N HCl in EtO 2 , stir the mixture overnight, filter and recrystallize to so-obtained solids from isopropanol/water. Cool, filter and dry the desired product, mp >300°C, Rf is 0.47 (eluted from silica with 10% cone. NH 3 /CH 3 OH).
- Step A N,N'-Bis((phenyl)methyl)-1,8-octanediamine
- Step B N,N'Bis((3-oxo)butyl)-N,N'-bis((phenyl)methyl)-1,8octanediamine
- Step A Dissolve the product obtained in Step A in 1400 ml of methanol and introduce 21.6 of methyl vinyl ketone on a stream of N 2 gas. Stir for 16 hours to yield the title compound.
- Step C N,N'-Bis((3-hydroxyimino)butyl)-N,N'-Bis- ((phenyl)methyl)-1,8-octanediamine
- Step D N,N'-Bis((3-amino)butyl)-N,N'-Bis((phenyl)-methyl)- 1,8-octanediamine
- Step E N,N'-Bis((3-amino)butyl)-1,8-octanediamine
- Step D Combine 5.0 g (0.01 mol) of the product of Step D, 0.5 g of 20% Pd(OH) 2 on carbon (Pearlman's Catalyst), and 50 ml or ethanol and treat the mixture with H 2 at 45 lb/in2 in a shaker flask until no more gas is taken up. Remove the catalyst by filtration and remove the solvent at reduced pressure. Subject the residue to short path distillation to yield 1.59 g of the title compound (bp 145-148°C at 0.012 mmHg).
- Step A N,N'-Bis[(phenyl)methyl]-1,7-heptanediamine
- Step C N,N'-Bis[(3-hydroxyimino)butyl]-N,N'-bis[(phenyl) methyl]-1,7-diaminoheptane
- step B Cool the reaction mixture obtained in step B to 0°C and to this mixture add a solution of hydroxylamine hydrochloride (4.38 g, 0.063 mol) and sodium bicarbonate (5.54 g, 0.066 mol) in water (40 ml). Stir the mixture at 0°C for 30 minutes and then stir at ambient temperature for 2 hours. Remove the solvent in vacuo and partition the residue between water (200 ml) and dichloromethane (200 ml). Wash the aqueous layer 3 times with 200 ml of dichloromethane each time. Combine the organic layers and dry over anhydrous MgSO 4 . Remove the solvent in vacuo to yield 14.4 g of the title compound. Rf is 0.53 for TLC on silica gel developed with ethyl acetate.
- Step D N,N'-Bis[3-(amino)butyl]-N,N'-bis[(phenyl) methyl]- 1,7-diaminoheptane
- Step E 2,16-Bis(methyl)-1,5,13,17-tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
- Step G N,N'-Bis[3-(methylamino)butyl]-1,7-diaminoheptane tetrahydrochloride
- Step A 1,17-Diethyl-2,16-dimethyl-1,5,13,17-tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
- Step B N,N'-Bis[3-(ethylamino)butyl]-1,7-diaminoheptane tetrahydrochloride
- HN(CH 2 ) 2 N(CH 2 ) 8 N(CH 2 ) 2 NHR' e.g., 1,16-Bis[(phenyl)methyl]-1,4,13,16-tetraazahexadecane•4 HCl.
- Step B Add a solution of the product of Step A in THF (150 ml) dropwise to a suspension of LAH (0.5 g) in THF (500 ml). Stir the mixture for 48 hours at ambient temperature. Decompose the excess reducing agent by dropwise addition of 1 ml of water, 1 ml of 15% NaOH then 3 ml of water. Filter the mixture and evaporate the filtrate. Take the residue up in ethanol (100 ml) and add anhydrous HCl gas to convert the product, 1,18-bis[(phenyl)ethyl]-5,14-bis-[(phenyl)methyl]1,5,14,18-tetraazaoctadecane, to its tetrahydrochloride salt.
- Step A N-(Phenyl-N,N'-bis(t-butoxycarbonyl)propanediamine Cool 200 ml of anhydrous Et 2 O in an ice bath and add lithium aluminum hydride (8.74 gm -0.23 mol). Add, in a dropwise fashion over 30 minutes, 3-anilinopropionitrile (14.6 gm) in 50 ml of Et 2 O, remove the ice bath, and reflux the resulting mixture overnight. Sequentially add 8.7 ml of water, 1.5 g of NaOH (in 10 ml of water) and 25 ml of water.
- Step B N-(t-Butoxycarbonyl)-2,3-butadienylamine
- Step D 1,18-Bis(hydroxy)-5,14-bis[(phenyl)methyl]-5,14-diazaoctadecane
- Step G 1,18-Bis(methanesulfonyl)-5,14-bis(t-butoxycarbonyl)- 5,14-diazaoctadecane
- Step H 1,18-Bis(2,3-butadienyl)-1,5,14,18-tetra-(t-butoxycarbonyl)-1,5,14,18-tetraazaoctadecane
- Step B 1,7-Bis(3-acetylhexahydropyrimidin-1-yl)heptane (MDL 44868)
- Step C 1,7-Bis(3-ethylhexahydropyrlmldln-1-yl)heptane (MDL 45692) A solution of crude bis(acetylhexahydropyrimidine) MDL
- Step D N,N'-Bis[3-(ethylamino)propyl]-1,7-heptanediamine tetrahydrochloride (MDL 28314QA)
- Step B 1,7-bis-p-Toluenesulfonamidoheptane
- Test compound numbers relate to the following
- MDL27,393 CH3CH2-NH-(CH2)3-NH-(CH2)8-NH-(CH2)3-NH- CH2CH3
- MDL27,616 ⁇ CH2-NH-(CH2)3-NH-(CH2)3-NH-CH2 ⁇
- N-(phenylmethyl)-N'[3-[(phenylmethylamino)propyl]-1,3- propanediamine MDL27,695 ⁇ CH2-NH-(CH2)3-NH-(CH2)7-NH-(CH2)3-NH- CH2 ⁇
- MDL28,314 CH3CH2-NH-(CH2)3-NH-(CH2)7-NH-(CH2)3-NH- CH2CH3
- MDL28,454 CH3CH2CH2-NH-(CH2)3-NH-(CH2)7-NH-(CH2)3- NH-CH2CH2CH
- Monolayers of human embryo fibroblasts (MRC-5 strain) were formed in the presence or absence of varying concentrations of compound and infected with CMV strain AD169 or Towne (100 pfu/10 5 cells) in the presence or absence of compound and incubated in the presence or absence of compound for ten days at 37°C. For incubation post infection, cell monolayers were overlaid in
- IC50 values for MDL27,393 (TABLE C1) and MDL28,314 (TABLE C2) were between 1-10 ⁇ moles/litre with the pre-post treatment protocol. No antiviral activity was observed in MRC-5 cells even at 100 ⁇ M with treatment post-infection only. In vero cells
- MRC-5 cells were seeded at low plating density and grown in the presence or absence of the preferred compound, MDL 27,393, or MDL 28,314 and cell numbers were determined at five days postseeding. The results showed that growth of these cells was not inhibited at concentrations of 0.5 ⁇ moles/litre or less although the time to confluency of the monolayers was longer compared to untreated controls at concentrations between 1 and 5 ⁇ moles/litre (data not shown).
- the therapeutic window for the preferred compound MDL 27,393, established by the amount of compound required to inhibit virus growth by 50% compared to the concentration required to inhibit cell growth by 50%, was greater than 10,000.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93921461A EP0662829A1 (en) | 1992-10-05 | 1993-09-10 | Polyamine derivatives as anti-cytomegaloviral agents |
AU48547/93A AU4854793A (en) | 1992-10-05 | 1993-09-10 | Polyamine derivatives as anti-cytomegaloviral agents |
JP6509077A JPH08512279A (en) | 1992-10-05 | 1993-09-10 | Polyamine derivatives as anti-cytomegalovirus agents |
KR1019950701292A KR950703335A (en) | 1992-10-05 | 1993-09-10 | Polyamine Derivatives as Anti-Cytomegaloviral Agents |
NO951299A NO951299L (en) | 1992-10-05 | 1995-04-04 | Polyamine derivatives as anti-cytomegaloviral agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929220921A GB9220921D0 (en) | 1992-10-05 | 1992-10-05 | Polyamine derivatives as anticytomegaloviral agents |
GB9220921.2 | 1992-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994007480A1 true WO1994007480A1 (en) | 1994-04-14 |
WO1994007480B1 WO1994007480B1 (en) | 1994-05-11 |
Family
ID=10722983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/008517 WO1994007480A1 (en) | 1992-10-05 | 1993-09-10 | Polyamine derivatives as anti-cytomegaloviral agents |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0662829A1 (en) |
JP (1) | JPH08512279A (en) |
KR (1) | KR950703335A (en) |
AU (1) | AU4854793A (en) |
CA (1) | CA2146319A1 (en) |
GB (1) | GB9220921D0 (en) |
HU (1) | HUT72663A (en) |
NZ (1) | NZ256254A (en) |
WO (1) | WO1994007480A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009832A1 (en) * | 1993-10-07 | 1995-04-13 | Merrell Dow Pharmaceuticals Inc. | Novel process for preparing polyamine derivatives and intermediates thereof |
FR2749845A1 (en) * | 1996-06-18 | 1997-12-19 | Oreal | NOVEL BENZYL SUBSTITUTED (S) DERIVATIVES OF POLYALKYLENE POLYAMINES AND THEIR USE IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS |
US5831001A (en) * | 1990-10-24 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
US7491849B2 (en) | 2001-10-16 | 2009-02-17 | Progen Pharmaceuticals, Inc. | Oligoamine compounds and derivatives thereof for cancer therapy |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111989316B (en) * | 2018-01-30 | 2023-09-08 | 潘贝拉治疗股份有限公司 | Process for the production of (6S, 15S) -3,8,13,18-tetraazaeicosane-6, 15-diol |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399519A2 (en) * | 1989-05-23 | 1990-11-28 | Merrell Pharmaceuticals Inc. | Potentiating cell-mediated immunity utilizing polyamine derivatives |
-
1992
- 1992-10-05 GB GB929220921A patent/GB9220921D0/en active Pending
-
1993
- 1993-09-10 EP EP93921461A patent/EP0662829A1/en not_active Ceased
- 1993-09-10 NZ NZ256254A patent/NZ256254A/en unknown
- 1993-09-10 WO PCT/US1993/008517 patent/WO1994007480A1/en not_active Application Discontinuation
- 1993-09-10 JP JP6509077A patent/JPH08512279A/en active Pending
- 1993-09-10 KR KR1019950701292A patent/KR950703335A/en not_active Application Discontinuation
- 1993-09-10 CA CA002146319A patent/CA2146319A1/en not_active Abandoned
- 1993-09-10 AU AU48547/93A patent/AU4854793A/en not_active Abandoned
- 1993-09-10 HU HU9500982A patent/HUT72663A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399519A2 (en) * | 1989-05-23 | 1990-11-28 | Merrell Pharmaceuticals Inc. | Potentiating cell-mediated immunity utilizing polyamine derivatives |
Non-Patent Citations (8)
Title |
---|
A.J. BITONTI ET AL.: "Regulation of polyamine biosynthesis in rat hepatoma (HTC) cells by a bisbenzyl polyamine analogue", BIOCHEM. J., vol. 257, no. 3, 1989, pages 769 - 774 * |
A.S. TYMS ET AL.: "Inhibitors of polyamine biosynthesis block human cytomegalovirus replication", NATURE, vol. 297, no. 5868, 1982, pages 690 - 691 * |
A.S.TYMS ET AL: "An association between polyamine biosynthesis and symptomatic infection with human cytomegalovirus", LIFE CHEM. REP., vol. 9, 1991, pages 179 - 183 * |
J.R. CLARKE ET AL.: "Polyamine biosynthesis in cells infected with different clinical isolates of Human Cytomegalovirus", J. MED. VIROL., vol. 34, no. 4, 1991, pages 212 - 216 * |
M.L. EDWARDS ET AL.: "Synthesis and DNA-binding properties of polyamine analogues", J. MED. CHEM., vol. 34, no. 8, 1991, pages 2414 - 2420, XP000604818, DOI: doi:10.1021/jm00112a016 * |
N.J. PRAKASH ET AL.: "Antitumor activity of a novel synthetic polyamine analogue, N,N'-Bis-[3-(ethylamino)-propyl]-1-7-heptane diamine: Potentiation by polyamine oxidase inhibitors", ANTICANCER RES., vol. 10, no. 5A, 1990, pages 1281 - 1288 * |
R. BERKOW ET AL.: "THE MERCK MANUAL", 1987, MERCK SHARP & DOHME RESEARCH LAB., RAHWAY, N.J. * |
W. GIBSON ET AL.: "D,L-alpha-Difluoromethylornithine inhibits Human Cytomegalovirus replication", JOURNAL OF VIROLOGY, vol. 50, no. 1, 1984, pages 145 - 154 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831001A (en) * | 1990-10-24 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
WO1995009832A1 (en) * | 1993-10-07 | 1995-04-13 | Merrell Dow Pharmaceuticals Inc. | Novel process for preparing polyamine derivatives and intermediates thereof |
US5756739A (en) * | 1993-10-07 | 1998-05-26 | Merrell Pharmaceuticals Inc. | Process for preparing polyamine derivative and intermediates thereof |
US5874627A (en) * | 1993-10-07 | 1999-02-23 | Merrell Pharmaceuticals Inc. | Process for preparing polyamine derivatives and intermediates thereof |
FR2749845A1 (en) * | 1996-06-18 | 1997-12-19 | Oreal | NOVEL BENZYL SUBSTITUTED (S) DERIVATIVES OF POLYALKYLENE POLYAMINES AND THEIR USE IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS |
EP0816324A1 (en) * | 1996-06-18 | 1998-01-07 | L'oreal | Subsituted benzyl derivatives of polyalkylene-polyamines and their use in cosmetic and pharmaceutical compositions |
US5910513A (en) * | 1996-06-18 | 1999-06-08 | L'oreal | Substituted benzyl derivatives of polyalkylene polyamines and their use in cosmetic and pharmaceutical compositions |
US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
US7491849B2 (en) | 2001-10-16 | 2009-02-17 | Progen Pharmaceuticals, Inc. | Oligoamine compounds and derivatives thereof for cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
EP0662829A1 (en) | 1995-07-19 |
JPH08512279A (en) | 1996-12-24 |
AU4854793A (en) | 1994-04-26 |
HU9500982D0 (en) | 1995-06-28 |
GB9220921D0 (en) | 1992-11-18 |
NZ256254A (en) | 1997-04-24 |
HUT72663A (en) | 1996-05-28 |
KR950703335A (en) | 1995-09-20 |
CA2146319A1 (en) | 1994-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7186825B2 (en) | Conformationally restricted polyamine analogs as disease therapies | |
CA1338764C (en) | Polyamine derivatives | |
US5109024A (en) | Polyamine derivatives as antineoplastic agents | |
US20090124832A1 (en) | Oligoamine compounds and derivatives thereof for cancer therapy | |
AU679972B2 (en) | Polyamine derivatives as radioprotective agents | |
US5654484A (en) | Polyamine derivatives as antineoplastic agents | |
AU608373B2 (en) | Polyamine derivatives as antineoplastic agents | |
EP0536853B1 (en) | Process for the preparation of N1,N4-diethylspermine | |
EP0399519B1 (en) | Potentiating cell-mediated immunity utilizing polyamine derivatives | |
WO1994007480A1 (en) | Polyamine derivatives as anti-cytomegaloviral agents | |
US5719193A (en) | Method of potentiating cell-mediated immunity utilizing polyamine derivatives | |
EP0046713B1 (en) | Fluorinated pentene diamine derivatives | |
EP0378146B1 (en) | Polyamine derivatives as antineoplastic agents | |
US5753714A (en) | Polyamine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 256254 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993921461 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2146319 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 403889 Country of ref document: US Date of ref document: 19950424 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993921461 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1993921461 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993921461 Country of ref document: EP |